(Reuters) - Pfizer Inc beat analysts' estimate for adjusted profit on Tuesday, helped by strong demand for its pneumonia vaccine Prevnar and rheumatoid arthritis drug Xeljanz, while reporting an $11 billion gain from the new tax law.